All In Biotech

Drug Trial Radar · NCT06774144

Rezafungin Prophylaxis in Liver Transplant

Rezafungin Prophylaxis in Liver Transplant at High Risk for Invasive Fungal Infection

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

385

Planned (sponsor's estimate)

Start

Oct 15, 2025

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Fernanda P Silveira, MD, MSAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Melinta Therapeutics
First posted
Jan 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an interventional study to evaluate the efficacy of rezafungin, a new echinocandin, for the prevention of invasive fungal infections (IFIs) after liver transplantation. Patients who receive rezafungin will be compared to a similar group of patients who underwent liver transplantation in the preceding two years for the incidence of IFIs.

Conditions

  • Liver Transplant Infection
  • Fungal Infection

Interventions

  • RezafunginDrug

    Rezafungin 400 mg IV once within 24 hours of liver transplant, followed by 200 mg IV weekly for 4 weeks.

  • Standard of care antifungal prophylaxisDrug

    UPMC uses a tiered approach to antifungal prophylaxis, based on risk factors for IFI. Fluconazole is used for recipients with risk factors for yeast infections: choledochojejunostomy, prolonged transplant time, receipt of \>40 units of blood products within 24 hours of transplant, and Candida colonization or infection within 3 months prior to transplant. Voriconazole is used for recipients with risk factors for mould infections: re-transplantation, renal failure requiring renal replacement therapy, fulminant hepatic failure as indication for transplant, intra-abdominal/thoracic re-exploration within the first month after transplant. No prophylaxis is given if there are no risk factors for yeast or mould infections.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of proven and probable IFIsTime frame: 90 days post-transplant
  2. Incidence of proven and probable breakthrough IFITime frame: While receiving rezafungin, voriconazole, or fluconazole

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UPMC Presbyterian

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.